Background: The association between vitamin D receptor gene Bsm I  (rs1544410) polymorphism and prostate cancer (PCa) risk has been investigated by numerous previous studies, which yielded inconsistent results. We conducted this meta-analysis to derive a relatively precise description of this association.
Methods: All studies published up to December 2017 were identified via a systematic search of PubMed, Embase, and China National Knowledge Infrastructure databases. Pooled odds ratios (ORs) with their 95% confidence intervals (CIs) were estimated to describe the strength of the relationship between Bsm I  and PCa risk.
Results: In this meta-analysis, 27 studies with 9,993 cases and 9,345 controls were included. The pooled results revealed that Bsm I  polymorphism was not associated with PCa risk in the overall analysis. Moreover, no significant relationship was found in the subgroup analyses by ethnicities, genotyping methods, Hardy–Weinberg equilibrium status, and Gleason score. In the stratified analysis by the source of controls and clinical stages, controls of benign prostatic hyperplasia (BPH) seemed to be in the particular groups in which the association of PCa risk with Bsm I  polymorphism was significant (Bb vs. bb: OR=0.643, 95% CI=0.436–0.949, p =0.026; BB/Bb vs. bb: OR=0.627, 95% CI=0.411–0.954, p =0.029; B vs. b: OR=0.715, 95% CI=0.530–0.965, p =0.029).
Conclusion: Our results suggest that Bsm I  polymorphism is weakly associated with PCa risk, and hence, it cannot be considered as a predictor of the occurrence and development of PCa in clinical practice. Future studies with a larger number of samples are needed to verify our results.
Keywords: Bsm I , prostate cancer, vitamin D receptor, polymorphisms, meta-analysis